Crescent Biopharma Inc. (CBIO)
NASDAQ: CBIO
· Real-Time Price · USD
11.72
-0.31 (-2.58%)
At close: Oct 03, 2025, 3:59 PM
11.72
0.00%
After-hours: Oct 03, 2025, 05:45 PM EDT
Company Description
Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients.
Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors.
The company is headquartered in Waltham, Massachusetts.
Crescent Biopharma Inc.
| Country | United States |
| IPO Date | Jan 10, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Joshua T. Brumm |
Contact Details
Address: 300 5th Avenue Waltham, Massachusetts United States | |
| Website | https://crescentbiopharma.com |
Stock Details
| Ticker Symbol | CBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001124105 |
| CUSIP Number | 14888D208 |
| ISIN Number | US4037831033 |
| Employer ID | 56-2020050 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bruce Johnson | Senior Vice President & Chief Commercial Officer |
| Chinmaya Rath | Senior Vice President & Chief Business Officer |
| Christian B. Dinneen-Long | General Counsel & Company Secretary |
| Shantha Tyavanagimatt Ph.D. | Senior Vice President of Technical Operations |
| Stephanie R. Irish CPA | Vice President of Accounting |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 10, 2025 | 8-K | Current Report |
| Aug 26, 2025 | 4 | Filing |
| Aug 26, 2025 | 3 | Filing |
| Aug 22, 2025 | 8-K | Current Report |
| Aug 20, 2025 | SCHEDULE 13G | Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 11, 2025 | 10-Q | Quarterly Report |
| Aug 11, 2025 | 8-K | Current Report |
| Aug 07, 2025 | 4 | Filing |